sch 58261 has been researched along with levodopa in 1 studies
| Studies (sch 58261) | Trials (sch 58261) | Recent Studies (post-2010) (sch 58261) | Studies (levodopa) | Trials (levodopa) | Recent Studies (post-2010) (levodopa) |
|---|---|---|---|---|---|
| 46 | 0 | 14 | 17,774 | 1,900 | 4,946 |
| Protein | Taxonomy | sch 58261 (IC50) | levodopa (IC50) |
|---|---|---|---|
| integrase, partial | Human immunodeficiency virus 1 | 0.5939 | |
| lens epithelium-derived growth factor p75 | Homo sapiens (human) | 0.5939 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 2.88 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 3.729 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 2.146 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.258 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gaba, S; Gupta, GD; Monga, V; Patel, R; Saini, A; Singh, G | 1 |
1 review(s) available for sch 58261 and levodopa
| Article | Year |
|---|---|
Adenosine receptor antagonists: Recent advances and therapeutic perspective.
Topics: Dose-Response Relationship, Drug; Humans; Molecular Structure; Purinergic P1 Receptor Antagonists; Receptors, Purinergic P1; Structure-Activity Relationship | 2022 |